Paper Details

  1. Home
  2. Paper Details

Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.

Author: BeltramiM, BerettaL, CampieriM, Di MaurizioP, FornaciariG, GanioE, GionchettiP, MeucciG, UsaiP, VecchiM, de FranchisR

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Oral mesalazine was as effective as combined oral and topical mesalazine in inducing remission in patients with mildly to moderately active ulcerative colitis. A randomized controlled trial involving 130 patients found that both treatments led to a similar rate of clinical remission at 6 weeks, with no significant difference in time to remission or rate of endoscopic remission.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Oral and topical mesalazine formulations are effective in active ulcerative colitis, but little is known on the efficacy of combined treatment. AIM: To compare the efficacy of oral mesalazine vs. combined oral and topical mesalazine in mildly to moderately active ulcerative colitis. ME...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2001.00913.x

データ提供：米国国立医学図書館（NLM）

Oral vs. Combined Mesalazine Therapy for Ulcerative Colitis

Ulcerative colitis, a chronic inflammatory bowel disease, can cause discomfort and disruption to daily life. This research explores the effectiveness of different mesalazine treatment approaches in patients with mildly to moderately active ulcerative colitis. The study, a double-blind, double-dummy, randomized multicentre trial, compared oral mesalazine alone to combined oral and topical mesalazine therapy. The findings suggest that both treatment approaches are equally effective in inducing disease remission, providing patients with valuable treatment options.

Similar Efficacy for Different Mesalazine Treatments

Both the oral mesalazine group and the combined treatment group achieved similar rates of clinical remission and clinical remission/improvement. The rates of clinical remission were 82% for oral treatment and 87% for combined treatment (P=0.56). The mean time to remission was also similar, at 22.2 days for oral treatment and 20.2 days for combined treatment (P=0.29). These findings suggest that patients with mild active ulcerative colitis can choose either treatment option based on their individual preferences.

Treatment Options for Ulcerative Colitis

This research offers valuable insights into the treatment of ulcerative colitis. It's like having two reliable paths through the desert, both leading to the same oasis of relief. Patients can now discuss with their healthcare providers which treatment approach best suits their individual needs and preferences.

Dr. Camel's Conclusion

This research provides a welcome oasis of knowledge for patients seeking effective treatments for ulcerative colitis. It suggests that both oral and combined mesalazine therapy are equally effective in inducing remission. It's like finding two paths leading to the same destination, giving patients more choices and flexibility in their treatment journey.

Date :
  1. Date Completed 2001-02-22
  2. Date Revised 2019-08-31
Further Info :

Pubmed ID

11148445

DOI: Digital Object Identifier

10.1046/j.1365-2036.2001.00913.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.